Assembly of nuclear dimers of PI3K regulatory subunits is regulated by the Cdc42-activated tyrosine kinase ACK

Autor: Natasha S. Clayton, Millie Fox, Jose J. Vicenté-Garcia, Courtney M. Schroeder, Trevor D. Littlewood, Jonathon I. Wilde, Kadalmani Krishnan, Murray J.B. Brown, Claire Crafter, Helen R. Mott, Darerca Owen

Activated Cdc42-associated kinase (ACK) is an oncogenic nonreceptor tyrosine kinase associated with poor prognosis in several human cancers. ACK promotes proliferation, in part by contributing to the activation of Akt, the major effector of class 1A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41be413a469124b50749c5c7e055601e

Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.

Autor: Krishnan K; Kadalmani Krishnan, Levim Biotech, Chennai, India. Electronic address: krishnan@levimbiotech.com., Raman S; Kadalmani Krishnan, Levim Biotech, Chennai, India. Electronic address: srikar@levimbiotech.com., Anand Moses CR; Moses Diabetes and Medical Centre, Chennai, India. Electronic address: cramoses@hotmail.com., Rajesh RP; Aadhavvan Diabetes and Research Centre, Chennai, India. Electronic address: doctorrpr@gmail.com., Gupta A; Atul Gupta, Navitas Life Sciences, Bangalore, India. Electronic address: atul.gupta@navitaslifesciences.com., Mudaliar V; Atul Gupta, Navitas Life Sciences, Bangalore, India. Electronic address: venkatesan.balu@navitaslifesciences.com., Vimal J; Kadalmani Krishnan, Levim Biotech, Chennai, India. Electronic address: jatin@levimbiotech.com.

Publikováno v: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2024 Jan; Vol. 207, pp. 111034. Date of Electronic Publication: 2023 Dec 05.